Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate Fasting/Postprandial Serum Apolipoprotein B-48 (ApoB-48) Levels in Diabetic Participants With Normal to Moderately High Low Density Lipoprotein-C (LDL-C) Levels (MK-0653A-259 AM1)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Participant has an LDL-C ranging from ≥100 mg/dL to \<160 mg/dL.~* Patient has a triglyceride (TG) level of ≤500 mg/dL.~Exclusion Criteria:~* Participant treated with a lipid-lowering agent in the 6 weeks prior to Visit 1 (screening period).~* Participant has active liver disease or persistent unexplained serum transaminase elevations (≥2 x the upper limit of normal \[ULN\])~* Participant has increased creatine kinase (CK) (≥2 x ULN).~* Participant has a history of type 1 diabetes mellitus, ketoacidosis, or gestational diabetes mellitus.~* Participant has a history of alcohol and/or drug abuse.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Diabetic participants (Type: EXPERIMENTAL): Diabetic participants with normal to moderately high LDL-C
- Nondiabetic participants (Type: EXPERIMENTAL): Non-diabetic participants with normal to moderately high LDL-C

Based on this trial design, predict the completion outcome and termination type (if applicable).